ABIVAX Société Anonyme (ENXTPA:ABVX) Could Be 44% Undervalued As UC Data Lands
Abivax Société Anonyme (ENXTPA:ABVX) is back in focus after releasing new ABTECT Maintenance Part 2 data on its ulcerative colitis candidate obefazimod, followed closely by a large follow on equity offering.
See our latest analysis for ABIVAX Société Anonyme.
The latest data and capital raise have arrived after a steep run in ABIVAX Société Anonyme, with a 30 day share price return of 42.89% and a very large 1 year total shareholder return that signals strong momentum from earlier stages in its story. At the same time, the 7 day share price pullback of 4.07% hints at investors reassessing risk after the follow on equity offerings.
If you are weighing this kind of high growth potential against other themes in the market, it can be useful to see what else is catching attention through 129 healthcare AI stocks
ABIVAX Société Anonyme now trades about 13% below the average analyst price target and at what appears to be a steep intrinsic discount, yet the recent pullback signals caution, so how far does valuation really support the story?
Most Popular Narrative: 44.3% Undervalued
The current €122.60 share price for ABIVAX Société Anonyme sits well below the €220 fair value implied in the most followed narrative, putting a spotlight on how bullish this view really is.
In my opinion, Abivax is worth much more than its current share price of around €136. The market still seems to value the company as if there is a lot of uncertainty, but I believe much of that uncertainty has now been reduced. The company's lead drug, obefazimod, has delivered strong Phase 3 results in ulcerative colitis, and recent safety updates have helped rebuild investor confidence. At the same time, Abivax has raised enough cash to fund its operations for several years, meaning it can focus on getting the drug approved and launched instead of worrying about raising more money.
Want to see what sits behind that €220 figure and 44.3% gap? According to Polip, the story leans on aggressive revenue expansion, improving margins and a future earnings multiple that assumes obefazimod becomes a major commercial product across more than one indication.
Result: Fair Value of €220 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, there are clear pressure points for ABIVAX Société Anonyme, including the risk that regulatory feedback on obefazimod or future financing needs could challenge this bullish valuation story.
Find out about the key risks to this ABIVAX Société Anonyme narrative.
Next Steps
With ABIVAX Société Anonyme pulling in both concerns and optimism, it makes sense to move quickly, review the data yourself, and weigh up the 2 key rewards and 2 important warning signs
Looking for more investment ideas beyond ABIVAX Société Anonyme?
If ABIVAX Société Anonyme is on your radar, do not stop there. Expand your watchlist now so you are not late to the next opportunity.
- Target potential mispricing early by scanning 211 high quality undervalued stocks that combine quality fundamentals with room for a rerating.
- Strengthen your income focus by reviewing 469 dividend fortresses that pair higher yields with staying power.
- Dial down portfolio risk by filtering for 290 resilient stocks with low risk scores built on resilient balance sheets and steadier fundamentals.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com